The search for an edge in the hot protein degrader space has led Novartis to Dunad Therapeutics. By putting up $24 million and committing to $1.3 billion in biobucks, Novartis has secured the chance to option candidates against up to four targets worked on by its new partner. Dunad exited stealth earlier this year with financing from Epidarex Capital and plans to use tunable monovalent small molecules to directly modify targets and thereby enable selective degradation. Source: Fierce Biotech 2/11/2021